Q-omics provides the consensus-scored KCTD5P1 profile across patient tissues and cancer cell-line models. KCTD5P1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KCTD5P1 is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, KCTD5P1 RNA expression shows 17,443 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KICH, and UVM as cancer lineages where KCTD5P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD5P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD5P1 survival associations across molecular data types. KCTD5P1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD5P1 RNA expression–survival associations across cancer types. High KCTD5P1 expression shows unfavorable associations in ACC, READ and LGG, but favorable associations in HNSC, KIRC and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KCTD5P1 RNA expression.
This table summarizes KCTD5P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for KCTD5P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD5P1 shows lower tumor expression in KICH and PRAD and higher tumor expression in STAD, ESCA, PAAD and UCEC. The KICH box plot shows higher KCTD5P1 RNA expression in normal versus tumor tissue (log2 FC = −0.303, t-test p < 0.001).
This table shows molecular features associated with KCTD5P1 in patient tissues and cancer cell lines. In patient samples, KCTD5P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
